VMAT-based pediatric TBI achieved organ sparing with acceptable early clinical outcomes
VMAT-TBI achieved 96.6% mean PTV D95 while keeping mean lung and kidney doses below 9 Gy.
VMAT-TBI achieved 96.6% mean PTV D95 while keeping mean lung and kidney doses below 9 Gy.
Patient-specific stents improved tongue and parotid stability and were associated with substantially less hearing loss, dysphagia and dysgeusia.
uTPS generated Halcyon VMAT plans with generally comparable dosimetry to Eclipse and greater than 97% gamma passing rates.
Twelve VMAT lattice courses produced 65% median tumor shrinkage and no local progression during short follow-up in bulky hepatocellular carcinoma.
In eight bulky tumor sites, flattening-filter VMAT lattice radiotherapy produced 75% symptom relief with no grade 3 or higher acute toxicity.
AI-assisted planning cut average planning time from about two hours to 30 minutes, but three of 12 plans required manual hotspot correction.
A phantom-derived model predicted SCART central target radius with R² values of 0.991–0.999, but clinical validation remains absent.
Early three-dimensional CBCT shifts performed no better than chance for identifying patients with at least 3% PTV coverage loss.
A standardized knowledge-based VMAT workflow achieved high target coverage, low cardiopulmonary doses and no grade 3 acute toxicity in 484 patients.
Surface-guided radiotherapy kept mean setup shifts near zero during frog-leg vulvar volumetric modulated arc therapy.
Aperture irregularity and modulation complexity score were the strongest plan-complexity predictors of patient-specific quality assurance pass rate.
Across 500 clinical cases, automated planning preserved target coverage and was associated with lower doses to multiple critical structures than earlier manual planning.